NCT02195011 - Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 4, 2017

Study Completion Date

June 4, 2017

Conditions

Colorectal Neoplasms

Interventions

DEVICE

SIR-Spheres

Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.

DRUG

Regorafenib

All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.

Trial Locations (3)

Florida Cancer Specialists - North, St. Petersburg

Tennessee Oncology PLLC, Nashville

Research Medical Center, Kansas City